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Abstract
Background
HIV surveillance requires monitoring of new HIV diagnoses and differentiation of incident
and older infections. In 2008, Switzerland implemented a system for monitoring incident
HIV infections based on the results of a line immunoassay (Inno-Lia) mandatorily conducted
for HIV confirmation and type differentiation (HIV-1, HIV-2) of all newly diagnosed patients.
Based on this system, we assessed the proportion of incident HIV infection among newly
diagnosed cases in Switzerland during 2008-2013.
Methods and Results
Inno-Lia antibody reaction patterns recorded in anonymous HIV notifications to the federal
health authority were classified by 10 published algorithms into incident (up to 12 months)
or older infections. Utilizing these data, annual incident infection estimates were obtained in
two ways, (i) based on the diagnostic performance of the algorithms and utilizing the rela-
tionship ‘incident = true incident + false incident’, (ii) based on the window-periods of the
algorithms and utilizing the relationship ‘Prevalence = Incidence x Duration’. From 2008—
2013, 3’851 HIV notifications were received. Adult HIV-1 infections amounted to 3’809
cases, and 3’636 of them (95.5%) contained Inno-Lia data. Incident infection totals calcu-
lated were similar for the performance- and window-based methods, amounting on average
to 1’755 (95% confidence interval, 1588—1923) and 1’790 cases (95% CI, 1679—1900),
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respectively. More than half of these were among men who had sex with men. Both meth-
ods showed a continuous decline of annual incident infections 2008—2013, totaling -59.5%
and -50.2%, respectively. The decline of incident infections continued even in 2012, when a
15% increase in HIV notifications had been observed. This increase was entirely due to
older infections. Overall declines 2008—2013 were of similar extent among the major trans-
mission groups.
Conclusions
Inno-Lia based incident HIV-1 infection surveillance proved useful and reliable. It represents
a free, additional public health benefit of the use of this relatively costly test for HIV confirma-
tion and type differentiation.
Introduction
The prevalence of HIV infection is relatively high in Switzerland. Between 0.3% and 0.5% of
the Swiss adult population were infected with HIV in 2012, and there were 16’000–27'000 per-
sons alive with HIV [1]. The epidemic started in the 1970s, and the cases notified to the Swiss
Federal Office of Public Health (SFOPH) rose rapidly after HIV screening had been introduced
in 1985. Notifications decreased during 1992–2000, but rose again by 25% in 2002. The new
diagnoses remained relatively stable during the next few years. Among men who had sex with
men (MSM), however, the annual notifications almost doubled between 2004 and 2008, while
they decreased in most other transmission groups, particularly among persons with heterosex-
ual transmission (HET). Between 2009 and 2013, the notifications generally decreased for all
groups, but with a transient 15% increase in 2012 for both MSM and HET [2]. This renewed
increase was an object of great concern to those involved in the HIV prevention campaign.
Case surveillance is important, but not sufficient because, due to the long and variable time
from infection to diagnosis, it does not reflect actual patterns of HIV transmission. This is why
tests for recent infection (TRIs) were developed. Most of them exploit the fact that the HIV-
specific antibody response evolves during the first few months of infection with respect to con-
centration, proportion of total IgG, isotype, avidity, or target antigen pattern [3–6]. Other TRIs
are based on the growing diversity of the genotypic HIV variants in a patient [7–9]. The appro-
priate use of TRIs has been described by a WHO technical report [10]. Common to serology-
based TRIs is the need for conducting a special assay that is not part of the diagnostic routine.
Systems for prospective country-wide incident HIV-1 infection monitoring based on TRIs
were introduced in France in 2003 and in Great Britain in 2009 [11,12]. In the U.S.A., the HIV
incidence between 1977 to 2006 was retrospectively estimated based on extrapolation and
extended back-calculation of results of a TRI performed in a 17% sample of patients newly
diagnosed in 22 states during 2006 [13].
Switzerland has chosen a different approach for monitoring incident HIV infection. We
demonstrated in 2007 that a patient’s antibody reaction in a widely used confirmatory line
immunoassay, the Inno-Lia HIV I/II Score assay (Inno-Lia), also provides information on the
duration of infection [14]. The Inno-Lia measures antibodies to different HIV antigens in a
standardized, semi-quantitative way. As both the pattern and intensity of HIV-specific anti-
bodies evolve during the first months after infection, it is possible to define algorithms (Alg)
which, with a certain diagnostic sensitivity and specificity, recognize antibody patterns charac-
teristic of early HIV-1 infection. If the diagnostic sensitivity and specificity of an algorithm are
Proportion of Recent HIV Infection in Switzerland
PLOS ONE | DOI:10.1371/journal.pone.0131828 July 31, 2015 2 / 21
Source, and Labor Synlab Luzern provided support in
the form of salaries for authors DC, CA & MB
respectively, but did not have any additional role in
the study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
The specific roles of these authors are articulated in
the ‘author contributions’ section.
Competing Interests: DC is an employee of Institut
Dr. Viollier AG. CA is an employee of Clinique de la
Source. MB is an employee of Labor Synlab Luzern.
There are no patents, products in development or
marketed products to declare. This does not alter the
authors' adherence to all the PLOS ONE policies on
sharing data and materials.
known, which requires prior testing of suitable reference groups of either less or more than 12
months duration of infection, it is possible to estimate the number of incident cases by means
of the simple diagnostic rule ‘ntested incident = ntrue incident + nfalse incident’, whereby true-incident
and false-incident are calculated based on pre-determined values for diagnostic sensitivity and
specificity [14]. Alternatively, if the window periods of the algorithms are known, it is also pos-
sible to use the relationship ‘Prevalence = Incidence x Duration’ [5,15].
In previous work, we have determined the diagnostic sensitivity and specificity of more
than 20 different Inno-Lia algorithms for differentiating between HIV-1 infections of less or
more than 12 months duration. A large study with patients who had been infected for at least
12 months and were selected to represent all clinical stages and major clades of HIV-1, was
undertaken to study the specificity of the incident infection algorithms [16]. Of the 714 patients
investigated, only 94 were infected by HIV-1 subtype B, while 620 patients were infected by
one of 15 different non-B clades including subtypes A, C, D, F, G, H, J, K, and circulating
recombinant forms (CRF) 01_AE, 02_AG, 03_AB, 06_CPX, 12_BF and 13_CPX. The study
showed that none of these non-B clades impaired the diagnostic specificity of the method.
Although a HIV-1 RNA load below 50 copies/mL significantly reduced the specificity among
patients receiving antiretroviral treatment (ART), increasing age was the sole factor which
weakly impaired the test specificity in untreated patients [16]. In another study, we assessed
the diagnostic performance of the algorithms based on 527 incident and 740 older infections.
The ten best-performing algorithms had a mean sensitivity of 59.4% for recognizing infections
of up to 12 months duration and a mean specificity of 95.1%. Using these ten algorithms in
combination, we identified distinct changes between the incident infection ratios (IIR) of four
successive annual cohorts of HIV-1 notifications [17]. In a further study, we determined the
window periods of all algorithms and calculated the IIR for the same four annual cohorts, but
based on the relationship ‘Prevalence = Incidence x Duration’. The resulting IIRs and their
changes were very comparable to those determined based on test performance [18].
In 2007, Switzerland adopted a new testing and data-reporting system for HIV confirmation
with the intention to put Inno-Lia based incident infection assessment into countrywide prac-
tice. Under the guidance of the Swiss National Center for Retroviruses (SNCR), 11 regional
notification labs perform the confirmatory testing which, among other tests, comprises a man-
datory Inno-Lia for confirmation of HIV infection and differentiation between HIV-1 and
HIV-2. These labs notify all results, including those of the Inno-Lia, by e-mail to the SFOPH.
This system has worked very well and, since 2008, has provided prospectively collected and
increasingly complete data for a population-based assessment of incident HIV infection.
In the present study, the laboratory notification data collected 2008–2013 were linked with
supplemental clinical and epidemiological information notified to the SFOPH by the patients’
attending physicians. The linked data were used for studying the dynamics of the HIV epi-
demic in different transmission groups. Of special interest was the question whether the sud-
den increase of HIV notifications observed in 2012 after three years of continuous decline was
due to an increase in actual HIV transmissions or rather to a more frequent diagnosis of older
infections.
Methods
Data origin and ethics statement
The present cross-sectional study investigated data contained in the regular, anonymized HIV
notifications prospectively sent to the SFOPH for patients newly diagnosed with HIV infection
between Jan 2008 and Dec 2013. There were two types of notifications for each patient: (i) a
laboratory notification with the diagnostic test data sent in by one of the 11 HIV notification
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PLOS ONE | DOI:10.1371/journal.pone.0131828 July 31, 2015 3 / 21
labs or the SNCR, and (ii) a supplemental clinical notification forwarded by the patient’s
attending physician, with epidemiologic and clinical information relevant in the context of
HIV infection. No informed consent was needed, since both types of anonymous notifications
are imposed by Swiss federal law.
Organization of HIV confirmation and notification
For a detailed description see S1 File. In brief, as soon as a notification laboratory has firmly
established the diagnosis of HIV positivity, it sends the test results and the SFOPH’s supple-
mental HIV notification form to the patient’s attending physician. The physician completes
the form and forwards it to the SFOPH. The notification laboratory enters the test results into
a dedicated Excel macro-sheet and mails it electronically to the SFOPH. Thus, at the end, every
HIV notification should comprise both the laboratory’s and the physician’s notification, and
the two sets of data are linked by the SFOPH.
The HIV notification laboratories are commissioned by the SFOPH and accredited accord-
ing to the ISO/IEC 17025 standard by the governmental Swiss Accreditation Service SAS
http://www.seco.admin.ch/sas/index.html?lang = en. The likewise accredited SNCR has been
commissioned since 1985 by the SFOPH to serve as the national HIV reference laboratory.
Serological differentiation between incident and older HIV-1 infection
Detailed results of the Inno-Lia HIV I/II Score assay (Fujirebio, formerly Innogenetics, Ghent,
Belgium) were taken from the laboratory notifications sent to the SFOPH. The Inno-Lia is a
CE-marked (conforming with the diagnostic standards of the European Union) line immuno-
assay that measures antibodies against recombinant proteins or synthetic peptides of HIV-1 or
HIV-2, which are coated as 7 lines on a nylon strip (S1 Fig). As each test strip also contains
three quantitative internal standards indicating different intensities, a semi-quantitative rank-
ing of the antibody reactions is possible [19,20]. Antibody reaction to each of the 7 HIV antigen
bands present on the test strips (sgp120 [including HIV-1 group O peptides], gp41, p31, p24
and p17 of HIV-1, and sgp105 and gp36 of HIV-2) was assessed either visually or by the auto-
mated scanner–based LIRAS system (Fujirebio, formerly Innogenetics). Based on the three
internal standards, which define reaction levels of +/−, 1+, and 3+ for each test strip, the anti-
body reaction to each HIV antigen was classified into one of six possible intensity scores (-, ±, 1
+, 2+, 3+, 4+) either visually according to instructions in the manufacturer’s test kit insert or
by the manufacturer’s automated LIRAS reading system. In the laboratory notification, these
values are transferred to numerical values (0, 0.5, 1, 2, 3, or 4). For the present study, only the
antibody reaction to HIV-1 was of relevance. Therefore, each patient’s pattern of antibodies to
the five HIV-1 antigens gp120, gp41, p31, p24 and p17 was subjected to analysis by each of 10
different Inno-Lia incident infection algorithms (see below). Previous investigation has shown
that the mode of Inno-Lia evaluation (visual or automated) does not affect the incident infec-
tion result [16].
Inno-Lia incident infection algorithms
Twenty-six algorithms (Alg) for incident HIV-1 infection, all described in [17], were developed
empirically by investigating which Inno-Lia antibody patterns were found at maximal fre-
quency in a group of patients with less than 12 months duration of infection (= recent or inci-
dent infection) and at minimal frequency in a group of patients with12 months duration of
infection (= older infection), as described in detail earlier [14,16,17]. The 10 best-performing
algorithms, listed in S1 Table, were applied to the collected Inno-Lia data of the present study.
Proportion of Recent HIV Infection in Switzerland
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Thus, each notified Inno-Lia result was classified by each of these 10 algorithms as representing
either an incident or older HIV-1 infection.
Window periods, determination of incident infection ratio and statistics
The window periods of the selected 10 best algorithms, defined as the duration of HIV-1 infec-
tion after which, according to a given algorithm, all samples would be classified as representing
an older infection, were taken from [18] and are listed in S1 Table.
The incident infection ratio (IIR), i.e., the proportion of incident among all newly diagnosed
infections, was determined among those patients that had an Inno-Lia result, as described in
the next two paragraphs. Annual numbers of incident infections were then obtained by multi-
plying the annual number of notifications with the IIR, thereby extrapolating missing Inno-Lia
data.
For window-based calculations, the equation IIRW = ntested incident/ntested  365/window was
used, wherein ntested equals the number of annual notifications [15]. The raw IIRW thus
obtained for each algorithm was furthermore adjusted for that algorithm’s pre-determined
diagnostic specificity (raw IIRW x %Specificity/100) [17], assuming that all assay parameters,
i.e., window periods, sensitivity and specificity remained constant during the study.
Performance-based IIR (IIRP) was calculated based on the relationship ntested incident = ntrue-
incident + nfalse-incident, wherein ntrue-incident = ntested × IIRP × %Sensitivity/100 and nfalse-incident =
ntested × (1 − IIRP) × (1 −%Specificity/100). Therefore, as published previously [14,17,18], IIRP
= (ntested incident / ntested + %Specificity/100 − 1) / (%Sensitivity/100 + %Specificity/100 − 1).
Results below zero were set to zero. This model again assumes that the assay performance
remains constant. Three different diagnostic sensitivities, S1, S2 and S3, were used; for details
refer to [17]. In short, S1 averages the diagnostic sensitivities found in that study for each algo-
rithm in the four quarters of the 12-months recent infection period. It corresponds to a model
that assumes an even distribution of diagnosing incident infections over all four quarters. This
model is probably incorrect, however, as many HIV-exposed individuals aware of their expo-
sure will seek early clarification of their HIV status. Sensitivity S2 thus accounts for this bias by
weighting the number of cases each quarter contributes to the total number of cases. Thus, the
adjusted, weighted sensitivities S2 were calculated by multiplying the quarter sensitivities used
for determination of S1 with the percentage of cases a quarter contributed to total cases and
then averaging the products. Sensitivity S3 further adjusts for bias exerted by symptomatic
patients, who are more likely to be diagnosed than asymptomatic individuals. For determina-
tion of S3, all cases judged incident because of reported signs or symptoms of ARS were
excluded and only the notifications with a previous negative HIV test were considered for the
calculation of diagnostic sensitivity. In comparison, sensitivity S1 is lowest, S2 is highest, and S3
is in-between; for details see the open access reference [17].
Correlations were assessed by Spearman’s rank correlation and linear regression analysis.
Influence of variables on incident infection result was assessed by multivariate logistic regres-
sion. Calculations and statistical analyses were performed either in Microsoft’s Excel or Stat-
View 5.0 for Macintosh (SAS Institute Inc., Cary, North Carolina, U.S.A.).
Results
Between Jan 2008 and Dec 2013, a total of 3’851 individuals newly diagnosed with HIV infec-
tion were notified to the SFOPH (Table 1). Of this total of notifications, 3’699 (96.05%) con-
tained Inno-Lia results, while the remaining 152 notifications (3.95%) didn’t. The proportion
of notifications without Inno-Lia data diminished over time from 12.4% in 2008 to 6.5% in
2009, about 1.2% each in 2010 and 2011, and zero in both 2012 and 2013.
Proportion of Recent HIV Infection in Switzerland
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Almost three-quarters of the notifications represented men. Transmission mode was domi-
nated by HET and MSM, which represented about 37% each of the total. Intravenous drug use
(IDU) was one order of magnitude less frequent (2.7%). Cases of transfusion-associated or
perinatally acquired HIV infection totaling 1.3% were predominantly found in individuals
infected abroad. The transmission mode was unknown (UKN) in 832 cases (21.6%). Totally,
3’826 patients were infected with HIV-1 (99.35%); 21 patients were infected with HIV-2, and 4
patients were dually infected with HIV-1 and HIV-2.
Assessment of incident infection in our study was restricted to HIV-1 infected persons that
were at least 16 years old. Thus, the 21 perinatally acquired HIV-1 infections and the 21 HIV-2
infections were excluded, leaving 3’809 patients for the evaluation, of whom 3’636 (95.46%)
presented with Inno-Lia data.
Continuous decline of annual incident HIV-1 infections 2008─2013
The Inno-Lia data of these 3’636 adult notifications were subjected to evaluation by the 10 algo-
rithms that distinguished best between incident and older HIV-1 infection, in order to decide
for each notification whether it represented an incident (12 months) or older infection. For
definition and diagnostic performance of these 10 algorithms, see S1 Table. Between a mini-
mum of 413 (11.4%, Alg09) and a maximum of 685 notifications (18.8%, Alg04.1), on average
Table 1. Characteristics of the 3’851 HIV notifications received 2008–2013.
Annual notiﬁcations (n, %)
2008 768 19.94
2009 658 17.09
2010 606 15.74
2011 564 14.65
2012 648 16.83
2013 607 15.76
Sex (n, %)
Male 2820 73.2
Female 994 25.8
unknown 37 0.96
Age, years (median, IQR) 37 30─45
Transmission mode (n, %)
HET 1428 37.08
MSM (including 29 MSM/IDU) 1438 37.34
IDU 103 2.68
Transfusion* 29 0.75
Perinatal** 21 0.55
Unknown 832 21.61
HIV type (n, %)
HIV-1 3826 99.35
HIV-2 21 0.55
Dual infection HIV-1 + HIV-2 4 0.10
With Inno-Lia results (n, %) 3673 96.03
IQR, interquartile range;
* all infected abroad;
** predominantly infected abroad
doi:10.1371/journal.pone.0131828.t001
Proportion of Recent HIV Infection in Switzerland
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571 cases (15.7%), were ruled incident by these 10 algorithms (Table 2). On first glance, the
number of infections ruled incident by the different algorithms decreased steadily between
2008 and 2013, but closer inspection showed that, in 2012, six algorithms ruled a higher num-
ber of infections incident than they did in 2011 (Algs 15.1, 15, 13, 07, 09, 04.1). The reason for
this cannot be explained at present. On average, however, the number of cases ruled incident
decreased from 2008 to 2011, plateaued in 2012, and decreased again in 2013.
The data of Table 2 were used to estimate annual incident infection ratios (IIR) in two ways,
(i) based on the pre-determined diagnostic performance (IIRP), and (ii) based on the pre-
determined window periods of the different algorithms (IIRW), as explained under Methods.
Application of the respective IIR to the number of annual notifications (including those few
that did not contain Inno-Lia data) then yielded the annual cases of incident infection. The cal-
culations leading to these estimates are shown in detail in S2 Table. The estimates of annual
incident infection for the 3’809 studied HIV-1 notifications, as well as their 95% confidence
intervals (95%CI), are shown in Tables 3 and 4; they are also visualized in the top panels
(labelled with “ALL”) of Fig 1.
Both methods yielded comparable totals of incident infection estimates, amounting to
1’755 cases for the performance-based method (Table 3) and 1’790 cases for the window-
based procedure (Table 4). Both methods indicated a continuous decrease of estimated
annual cases of incident infections in dependence of time between 2008 and 2013, from a
mean 454 cases to 184 cases (-59.5%) for the performance-based method and from a mean
432 to 215 cases (-50.2%) for the window-based method (Spearman’s correlation test,
P = 0.0253 for both methods). Significant decreases by both estimation methods were also
found for each of the 10 individual algorithms. The corresponding mean incident infection
rates, IIRP and IIRW, decreased to 51.0% and 63.3%, respectively, of their 2008 values (S2
Table). For 2012, when the notifications of new HIV diagnoses increased by 15% (from 557
cases in 2011 to 643 in 2012), neither method showed a rise in mean incident infections.
Thus, the 15% increase in adult HIV-1 notifications of 2012 was caused entirely by a higher
Table 2. HIV-1 infections ruled incident by the 10 best-performing Inno-Lia algorithms.
Year 2008─2013 2008 2009 2010 2011 2012 2013
Total notiﬁcations n = 3’636 n = 661 n = 599 n = 587 n = 549 n = 643 n = 597
Number of notiﬁcations ruled incident
Alg15.1 623 140 119 107 87 92 78
Alg15 644 141 122 110 93 97 81
Alg11.2 617 133 121 102 94 89 78
Alg13 560 126 106 95 81 82 70
Alg07 448 106 82 70 64 69 57
Alg09 413 100 75 66 58 62 52
Alg11.1 617 133 121 102 94 89 78
Alg12.1 627 136 122 105 96 89 79
Alg04.1 685 142 132 125 98 101 87
Alg08.1 480 110 91 76 73 69 61
Mean 571 127 109 96 84 84 72
(%) (15.7) (19.2) (18.2) (16.3) (15.3) (13.1) (12.1)
lower limit 95%CI 514 117 97 84 75 76 65
upper limit 95%CI 629 136 121 108 93 92 79
Analysis restricted to notiﬁcations that contained Inno-Lia results.
doi:10.1371/journal.pone.0131828.t002
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number of newly diagnosed older infections, while incident infections continued to decline
in this year, though only minimally.
Decline of annual incident infections for all major transmission modes
Assessment of incident HIV-1 infection for the different modes of transmission is shown in the
lower panels of Fig 1; the underlying calculations for both performance- and window-based
procedures are presented in S3 Table.
Table 3. Incident HIV-1 infection estimates utilizing the performance-basedmethod.
Year 2008─2013 2008 2009 2010 2011 2012 2013
Total notiﬁcations n = 3’809 n = 763 n = 649 n = 597 n = 557 n = 643 n = 600
Number of notiﬁcations estimated incident
Alg15.1 1749 461 360 295 226 225 182
Alg15 1721 444 354 290 233 225 176
Alg11.2 1668 425 363 268 245 199 168
Alg13 1604 429 330 267 217 199 161
Alg07 1792 479 341 268 243 255 207
Alg09 1699 467 320 260 226 234 193
Alg11.1 1609 416 356 259 236 187 156
Alg12.1 1653 430 360 271 244 187 160
Alg04.1 1559 385 341 297 205 184 146
Alg08.1 2498 602 511 407 375 315 287
Mean 1755 454 364 288 245 221 184
lower limit 95%CI 1588 417 330 261 216 196 158
upper limit 95%CI 1923 490 397 316 274 246 209
IIRP (%) 46.1 59.5 56.0 48.3 44.0 34.4 30.6
doi:10.1371/journal.pone.0131828.t003
Table 4. Incident HIV-1 infection estimates utilizing the window-basedmethod.
Year 2008─2013 2008 2009 2010 2011 2012 2013
Total notiﬁcations n = 3’809 n = 763 n = 649 n = 597 n = 557 n = 643 n = 600
Notiﬁcations estimated incident
Alg15.1 1899 466 372 314 255 266 226
Alg15 1919 460 373 316 266 274 230
Alg11.2 1754 414 353 280 257 240 211
Alg13 1695 417 329 277 236 235 202
Alg07 1615 417 303 243 221 235 195
Alg09 1514 400 282 233 204 215 181
Alg11.1 1742 411 351 278 255 238 210
Alg12.1 1744 414 348 281 257 235 209
Alg04.1 1861 423 369 328 256 260 225
Alg08.1 2151 503 427 348 322 288 264
Mean 1790 432 351 290 253 249 215
lower limit 95%CI 1679 412 326 267 234 235 201
upper limit 95%CI 1900 453 376 312 272 262 229
IIRW (%) 47.0 56.7 54.0 48.5 45.4 38.7 35.9
doi:10.1371/journal.pone.0131828.t004
Proportion of Recent HIV Infection in Switzerland
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Among the total of 1’437 notifications attributed to MSM, as many as 1’060 notifications
(73.8%) were estimated to represent incident infections based on IIRP, and 960 (66.8%) were
estimated to represent incident infections based on IIRW. The annual estimates of 234 or
respectively 206 incident cases for 2008 decreased to 122 (48% less than in 2008) or, respec-
tively, 116 estimated cases for 2013 (44% less). These decreases in dependence of time were
Fig 1. Number of HIV notifications and incident HIV infections over time, as obtained by performance-
based and window-based incident infection estimates. Panels on top labeled “All” show the data for all
patients, lower panels show the data per risk category (MSM, men who have sex with men; HET,
heterosexual transmission; IDU, intravenous drug use; UNK, unknown transmission pathway). In all panels,
the blue curve with the circle symbols denotes the annual number of HIV notifications, and the black curve
without symbols shows the estimated number of incident infections (means and their 95% confidence
intervals). The top panels also show the results obtained with the 10 individual algorithms (grey lines in the
background).
doi:10.1371/journal.pone.0131828.g001
Proportion of Recent HIV Infection in Switzerland
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significant for both methods (Spearman’s, P = 0.0275). Both methods indicated a plateau of
incident infections among MSM for 2009─2010, but neither method showed an increase in
2012, the year in which notifications among MSM had rebounded by 9% after three years of
continuous decline (panels “MSM” of Fig 1; calculations in sections 3A and 3B of S3 Table).
Of the total of 1’417 notifications attributed to HET, 358 (25.2%) were estimated to repre-
sent incident infections based on IIRP and 454 (32.1%) based on IIRW. Estimated annual cases
of incident infections decreased from 100 or respectively 111 cases in 2008 to 24 (-76%) or 48
cases (-57%), respectively, in 2013. Both methods showed an over-proportional decrease of
incident infections in 2010, followed by a transient increase in 2011 (panels “HET” of Fig 1;
sections 1A and 1B of S3 Table). Spearman’s rank correlation test indicated a trend for decrease
in dependence of time (p, 0.064 for both methods).
Of the 102 notifications attributed to IDU, 39 or respectively 43 cases were estimated to rep-
resent incident infections (38% or, respectively, 42%). The incident infection estimates of 17
(IIRP) or respectively 16 cases (IIRW) in 2008 decreased to 3 or respectively 4 cases in 2013,
indicating a five- to four-fold reduction (panels “IDU” of Fig 1; sections 2A and 2B of S3
Table).
Finally, among the 826 notifications with unknown (UKN) mode of transmission, there
were 239 (28.9%) or respectively 287 (34.7%) infections estimated incident. The annual figures
decreased from 92 or respectively 93 in 2008 to 26 or respectively 42 in 2013, indicating reduc-
tions by 72% or, respectively, 55% (panels “UKN” of Fig 1; sections 4A and 4B of S3 Table).
Note that among all patients, the curves of annual notifications and annual incident infec-
tion estimates decreased in parallel between 2008 and 2011 (Fig 1, top panels). During this
period, the differences between the annual numbers of notifications and estimated incident
infections amounted to an average of 299 (95%CI 282─316) for IIRP or, respectively, 305 (95%
CI 278─332) for IIRW. After 2011, the two curves diverged, because the number of notifica-
tions increased while the incident infection estimates continued to decrease. From 2012 to
2013, both curves decreased again more or less in parallel, but now with a larger distance in-
between; i.e., the difference increased to 420 for IIRP (95%CI 384─456) and, respectively, 391
for IIRW (95%CI 342─440). Thus, in 2012 and 2013, significantly higher numbers of older
infections were diagnosed than in the preceding four years.
Parallel curves for notifications and incident infections between 2008 and 2011 were also
observed for MSM and UKN, as well as for the few IDU (Fig 1, lower panels). Among HET,
however, the two curves varied more, indicating that diagnoses of both incident and older
infections varied considerably for consecutive years. Increases in notifications in 2012 were
observed for MSM, HET, IDU and, particularly, UKN (here also for 2013), showing that in
2012 older infections were diagnosed more frequently in all transmission groups.
MSM account for more than half of all incident infections
While total numbers of notifications were similar for MSM and HET (1437 and, respectively,
1417), MSM had a much higher proportion of incident infections. As a matter of fact, the
majority of the incident infections were due to transmissions among MSM. According to the
performance-based method, as many as 1060 (60.4%) of the mean estimated 1755 incident
infections were attributable to MSM, while 358 (20.4%) were attributable to HET, 39 (2.2%) to
IDU, and 239 (13.6%) to UKN (see Table 3 and S3 Table). Similarly, according to the window-
based method (Table 4 and S3 Table), MSM accounted for 960 (53.6%) of the estimated total
of 1790 incident infections, HET for 454 (25.4%), IDU for 43 (2.4%), and UKN for 287
(16.0%). As these are estimates and also partly because uncommon modes of transmission like
transfusion-associated infection were not considered, the figures do not add up completely to
Proportion of Recent HIV Infection in Switzerland
PLOS ONE | DOI:10.1371/journal.pone.0131828 July 31, 2015 10 / 21
the incident infection totals of Tables 3 and 4. A small percentage of these, 3.5% for perfor-
mance-based and 2.6% for window-based, is not accounted for.
Correction for selection bias
The incident infection estimates described above were obtained based on the assumption that
diagnosis of incident HIV infection would be evenly distributed over all four quarters of the
12-months incident infection period. It is likely, however, that many HIV-exposed individuals
seek early clarification of their HIV status, in particular if they experience symptoms of pri-
mary HIV infection (PHI). When using the performance-based method, such bias affects the
diagnostic sensitivity of the algorithms [17]. Thus, by using sensitivity S2 (see Methods), adjust-
ment is made for seeking early diagnosis after an experienced HIV exposure, and by using sen-
sitivity S3 the bias exerted by symptoms of PHI is adjusted for. The results of these models are
shown in Fig 2, and the underlying calculations are presented in S4 Table.
With adjustment for seeking early diagnosis (S2), annual incident infections were reduced
to 54% of the numbers obtained with S1 and they dropped from 245 in 2008 to 99 in 2013.
Analogous reductions were observed for the major transmission groups: for MSM, from 167
cases in 2008 to 66 in 2013; for HET, from 54 in 2008 to 13 in 2013. With the model adjusting
for bias due to symptoms of PHI (S3), annual incident infections were reduced to 76% of the
numbers obtained with S1, resulting in curves located in-between those of S1 and S2. Whatever
the model, the decrease of annual incident infections from 2008 to 2013 remains the same:
total incident infections dropped to 51% of their initial number.
Knowing now that adjustments for seeking early diagnosis (S2) or for symptoms of PHI (S3)
reduce the numbers of incident infections to 54% and 76%, respectively, we applied these
adjustments also to window-based incident infection estimates (Fig 2, panels on the right).
This is justified, because a linear relationship between the diagnostic sensitivity of the algo-
rithms and their window time has been demonstrated [18]. A proportional change in one of
these two parameters is thus accompanied by an equal proportional change in the other.
Discussion
Switzerland is one of the first countries with a comprehensive, country-wide system for moni-
toring incident HIV infections among newly diagnosed cases. The system is based on the
results of the Inno-Lia which, since 2006, has been mandatory for confirmation of all newly
diagnosed HIV infections and for differentiating between HIV-1 and HIV-2 [21]. Here we
have evaluated the notification data collected by the SFOPH during the first six years since the
system’s implementation in 2008 (Table 1). Based on Inno-Lia reaction patterns obtained pro-
spectively during confirmation of a newly diagnosed HIV-1 infection, we determined the num-
ber of infections that were ruled incident by the 10 best-performing Inno-Lia incident infection
algorithms (Table 2). We found that the average proportion of such incident pattern cases
among the notifications decreased gradually from 19.2% in 2008 to 12.1% in 2013. Utilizing
these empirically generated data and extrapolating them to all notifications, we estimated the
proportion of incident infections in two ways, (i) based on the diagnostic performance of the
algorithms (IIRP; Table 3), and (ii) based on the window periods of the algorithms (IIRW;
Table 4). The two methods yielded comparable estimates of total incident infections amounting
to 1755 and, respectively, 1790 cases, which corresponds to overall incident infection ratios of
46.1% and, respectively, 47.0%. The good agreement indicates that the diagnostic performance
of the 10 selected algorithms on the one hand and their window periods on the other hand are,
on average, correct.
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Both methods showed a statistically significant, continuous overall reduction of newly diag-
nosed incident infections between 2008─2013 (Tables 3 and 4; Fig 1 top panels). Moreover, the
reduction applied to all major transmission modes, again with similar curves for the two meth-
ods. Of note, incident infections continued to decrease in 2012 despite a 15% increase in HIV
notifications observed in this year (Fig 1). Though numbers of notifications among MSM and
HET were similar, MSM had a considerably higher proportion of incident infections. More
than half of the estimated incident infections were attributed to MSM, 20─25% to HET and
about 2% to IDU, while for the rest the transmission mode was unknown (Fig 1, lower panels).
Limitations
That the observed decrease of HIV-1 infections12 months duration among the newly noti-
fied cases is real, is supported by several lines of evidence. Statistically, the decrease was not
only significant when the algorithms were used as a group, but also when used individually.
However, when using these data for an estimation of HIV incidence in Switzerland, more elab-
orate statistics utilizing additional information like size and testing frequency of the different
Fig 2. Incident infection estimates based onmodels adjusting for possible selection bias. S1, no
adjustment; S2, model with adjustment for selection bias exerted by seeking early testing after a suspected
exposure; S3, model with adjustment for seeking medical attention due to symptoms of acute HIV infection.
Refer to Methods for further explanations. The blue curve without symbols on top in each panel shows the
number of HIV notifications.
doi:10.1371/journal.pone.0131828.g002
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transmission groups will be indispensable for defining the true extent of the observed reduc-
tions and assessing the associated uncertainties [22].
The validity of our results depends on the assumption that assay performance, i.e. the sensi-
tivity and specificity of the Inno-Lia and the algorithms used for result interpretation, remained
constant during the study period. For some other TRI, notably the BED incidence assay, it has
been shown, however, that the specificity depends on time since infection or, respectively,
decreases in patients with very advanced disease [23,24]. Modelling studies in which the pro-
portion of cases with advanced disease in an investigated population was varied have conse-
quently shown that errors in incidence estimates based on the BED assay could vary by place,
time and age-group, even if the proportion of truly incident infections did not change. Post-
assay adjustment procedures like correcting for a specificity predetermined in a different popu-
lation or established at a different time may thus not be valid in all situations [25]. We therefore
have to demonstrate that the conditions under which our study was conducted did not change
over time, or if they changed, that such changes could not explain the observed results.
With respect to assay performance, there is a possibility that the decline in incident infection
numbers could be due to an inadvertent increase in sensitivity of the Inno-Lia over time, lead-
ing to bands of increasing intensity for a given plasma or serum sample. Similarly, bands of
given intensity might over time be ruled to be of higher strength. Both types of variation would
manifest themselves in our study as antibody reactions of increasing average intensity over
time. We have checked such technical artifact by determining the average band intensity for all
five HIV-1 antigens over time. While there was some variation among both recent and older
infections, there was no trend for increase that could be correlated with, and explain, the
observed continuous reduction of incident infections (S2 File).
Another possible source of error relates to the assumption that the diagnostic specificity of
the Inno-Lia algorithms remained constant during the study. As HIV-specific antibody titers
decrease with disease progression [26–30], TRI may become false-recent. Thus, if the propor-
tion of patients with advanced disease in an investigated population increases over time, this
may result in an apparent increase of incident infections and vice-verse. As we observed a
decrease, we investigated whether this could be due to a reduction of patients with advanced
disease over time. This was not the case: the proportion of notifications with AIDS at diagnosis
increased from 10.3% in 2008 to 15.6% in 2010, and then decreased again to 9.3% by 2013. Pre-
vious work has shown furthermore that CDC stage C does not impair the specificity of the
Inno-Lia algorithms [16]. In contrast to TRIs like the BED incidence assay or tests based on
antibody affinity, which are solely based on signal/cutoff ratios, the Inno-Lia algorithms in
addition define band patterns that differ between early and late infection. In early infection,
reaction to p24 and p17 is generally stronger than to p31, because antibodies to p31 are the last
to appear [18,31,32]. In advanced infection, however, antibody reaction to p31 and the enve-
lope proteins is preserved, while that to p17 and p24 is diminished, due to an early down-
regulation in patients with disease progression [26–30]. Most of the Inno-Lia algorithms used
in this study specify that reaction to p17 and/or p24 be higher, or at least not lower, than that
to p31 (see S1 Table). This largely preserves the specificity in advanced infection.
It has also been reported that a low HIV viral load, be it as a consequence of ART or as seen
in elite virus controllers, is associated with a delayed antibody response and lower titers of
HIV-specific antibody titers, thus resulting in false recent TRI; this was also found for the
Inno-Lia algorithms [16,23,24,33–35]. However, since we perform the Inno-Lia at the time of
HIV diagnosis, ART-induced false-incident results should be absent. Still, a sizeable and over
time increasing presence of elite controllers in our study could have such an effect. This was
not the case, however, as the proportion of patients with viral load50 copies/mL was only
1.14%, though rising from 0.47% in 2008 to 2.3% in 2013. Of note, however, the rise did not
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occur among infections ruled incident, but among those ruled older. Thus, this mechanism did
not contribute to the observed 50% reduction of incident infections.
It has furthermore been suggested that individuals with a low HIV viral load are enriched
over time in a population, due to their higher probability to survive [25,33]. While this may
apply to countries where good medical care with access to ART is unavailable to the majority
of the inhabitants, such selection does not operate in a country like Switzerland that has an
excellent health care system accessible for all its inhabitants. Furthermore, it is unconceivable
that such selection could take place within the six years of the study. As a matter of fact, as
stated above, the proportion of cases with a viral load50 was only 1.14%. Actually, 26 of the
31 such cases were ruled older and, among these, the proportion increased from 0.6% in 2008
to 2.4% in 2013. Among cases ruled recent, there was never more than a single case per year.
Thus, such selection did not contribute to the observed decrease in incident infections.
Regarding age, it has been recognized that older population groups have a higher chance of
being in advanced stage of infection compared to young adults whose risk of getting infected
started only when reaching adolescence. With the BED incidence assay, older HIV positive
populations therefore also have a higher proportion of patients in advanced disease, thus
resulting in more false-recent TRI results [25]. In order to investigate this possibility, we
assessed the age of our patients over time and found no difference. Mean age amounted to 37.8
years in 2008, increased to 39.2 years in 2011, and decreased again to 38.4 years in 2013.
In order to further assess the influence of these factors when present in combination we per-
formed multivariate logistic regression. We used a model in which transmission risk, diagnosis of
AIDS in the year of diagnosis, sex, year of diagnosis, viral load50 copies/mL and age were the
independents and incident infection result by the top-ranking Alg15.1 was the dependent. These
data were available for 2700 cases, i.e. about 75% of the notifications with Inno-Lia results. Two
variables promoted an incident infection result: MSM compared to HET (p<0.0001; odds ratio
(OR), 1.963; 95% CI, 1.511–2.552), and being AIDS-free (p<0.0001; OR, 3.739; 95% CI, 2.437–
5.738). Two variables were associated with a decreased risk of an incident infection result, namely
female sex (p = 0.0015; OR, 0.606; 95% CI, 0.445–0.852) and increasing year of diagnosis
(p<0.0001; OR, 0.883; 95% CI, 0.833–0.936). Low viral load and age carried no significance
(p>0.7). Similar results were obtained for the other nine algorithms. Adding CD4+ counts to this
model reduced the available number of cases to 850. Having a high CD4+ T cell count clearly pro-
moted a result of incident infection (p = 0.0002; OR per additional 100 CD4+ cells, 1.125; 95% CI,
1.058–1.195). Being an MSM and being AIDS-free at diagnosis retained significance in this
model, while all other variables were non-significant. Thus, in contrast to the findings with the
BED incidence EIA, but in agreement with our earlier findings [16], the specificity of the Inno-Lia
algorithms was not impaired by age, viral load, or advanced stage of disease. We thus conclude
that the limitations that apply to the use of the BED incidence EIA as shown by [25] do not apply
to our study and that the assay performance characteristics, the diagnostic specificity and sensitiv-
ity, remained constant during the entire study period.
A weakness of most incident infection estimates is the fact that they are usually based on the
probably incorrect assumption that incident HIV infection will be diagnosed at a constant fre-
quency during the 12 months of the incident infection period. Indeed, it has been demon-
strated that illnesses associated with seroconversion and other factors promote diagnosis
within the initial quarter of this first year after infection, and methods for correcting such bias
have been presented by others [36]. In our study, we have also addressed this point and have
used two models that adjust for such selection bias (Fig 2). Although it is unknown which of
the models is the best one, they indicate the effects exerted by such biases. Independently of the
choice of model, the three models show that the proportion of incident HIV infection was
reduced by half during the study.
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As with other tests, the reliability of Inno-Lia based incident infection assessment depends
on the prerequisite that all factors other than the investigated variable remain unchanged dur-
ing the study. The Swiss dual notification procedure with both a laboratory and a physician’s
notification (see Methods) has been in operation for more than 20 years now and also provides
for effective recognition and exclusion of repeat notifications. As stated under Results, the pro-
portion of notifications with Inno-Lia result increased from 87.6% in 2008 to 100% in 20012
and 2013. It is difficult to see, however, how this change should have affected the proportion of
incident infection patterns among the notifications. The completeness of laboratory reporting
has also improved during the study; cases with a physician’s notification alone have entirely
disappeared in recent years. But again, it is difficult to see how this change could have biased
the results. We thus assume that the observed decrease in the proportion of incident HIV infec-
tions was not due to changes in the reporting system.
On the other hand, changes in testing behavior might also have influenced the results over
time. For example, even if the number of newly acquired infections didn’t change, the incident
infection ratio and, thus, the number of patients ruled to have incident infection, would
decrease if a sufficiently large proportion of the newly infected individuals chose to get tested
just a few months later than in previous years. However, in view of the fact that early HIV test-
ing has been recommended vigorously in recent years and of growing evidence that early initia-
tion of ART is beneficial for the long-term outcome of HIV-1 infection (evidence reviewed in
[37]), such an effect is unlikely to have impacted our study.
A distinct increase in diagnoses of syphilis and other sexually transmitted diseases was
observed among MSM between 2009 and 2013 in Switzerland, indicating that, as in other
countries, risk-taking behavior increased in this group [2]. It is thus surprising that during the
same time the number of observed incident infections should have decreased also among
MSM, and the question arises whether the observed decrease could be due to selection bias.
Could MSM with recent HIV infection be underrepresented in the present study? Data col-
lected in voluntary counseling and testing (VCT) centers in Switzerland, particularly the so-
called ‘Checkpoints’ targeted to the special needs of MSM, indicate that this is probably not the
case. HIV testing among MSM in such VCT centers increased about three-fold between 2009
and 2013, while testing among heterosexual men and women increased only little. In addition,
based on information contained in the physicians’ supplemental notifications (see Methods),
only 8% of the MSM, but 14% of the other transmission risk groups were considered to be late
presenters. Together these data suggest that HIV testing among MSM was more frequent than
among the other groups [2]. Thus, if there was bias at all, it was probably in favor of MSM with
recent HIV infection. Provided that the situation in VCT centers is representative of the total,
HIV incidence in MSM across Switzerland may thus have decreased even more than suggested
here. A clear assessment of HIV incidence is not possible, however, as numbers of HIV tests
performed in the country are unknown.
Causes for the decrease in newly diagnosed incident HIV infections
The causes of the decline of newly diagnosed incident HIV infections in Switzerland remain
unknown, but in theory may include any of the following: improved preventive behavior in the
population particularly at risk for HIV infection, earlier diagnosis of HIV infection, earlier start
of antiretroviral treatment (ART) resulting in fewer untreated patients and, therefore, a lower
risk of secondary transmission. The promotion of HIV testing among individuals at risk has
been a central goal of the national HIV prevention campaign during the past decade, but statis-
tics for the total number of HIV tests conducted each year in our country are lacking. That the
number of newly diagnosed HIV-1 infections of more than 12 months duration increased
Proportion of Recent HIV Infection in Switzerland
PLOS ONE | DOI:10.1371/journal.pone.0131828 July 31, 2015 15 / 21
significantly in 2012─2013 (Fig 1, top) may indicate that pre-existing infections were diag-
nosed more efficiently, possibly in response to an extension of the national HIV prevention
program to other sexually transmitted infections (STI) implemented in 2011 [38]. The effort to
increase public awareness to STI may have led to a higher detection of pre-existing HIV infec-
tions in individuals seeking medical assistance due to signs and symptoms of STI.
International treatment guidelines have recommended an ever earlier start of antiretroviral
treatment (ART). Guidelines implemented in the U.S. in 2012 recommend that all HIV
infected individuals receive ART while, in Europe, the use of ART should at least be considered
and actively discussed with the HIV-positive person [36,39]. As a consequence, the community
viral load and the number of individuals with an HIV load sufficiently high for virus transmis-
sion are expected to decrease more and more, leading to fewer and fewer transmissions [40–
42]. The statistics of the Swiss HIV Cohort Study (SHCS), in which significant proportions of
the HIV-infected individuals in Switzerland participate, namely 53% of the patients with an
HIV notification and 69% of the patients with an AIDS notification to the SFOPH, show that
the median CD4+ T-cell count at the initiation of ART in treatment-naïve patients has con-
stantly increased in recent years, particularly among MSM. Similarly, the proportion of non-
treated patients in the SHCS has continuously decreased from 20% in 2007 to 5.6% in July
2012 [43]. These data are compatible with, but not proof of, the notion that increased antiretro-
viral treatment of the HIV infected community may indeed have contributed to the observed
decrease of incident infections. A decrease in the community viral load would best explain the
changes; a study on that in the SHCS is in progress, but results are not yet available.
Strengths and weaknesses of Inno-Lia based incident infection
estimation
One major advantage of the Inno-Lia based estimation of incident HIV infection is the avail-
ability of a whole panel of algorithms, each with its own diagnostic sensitivity, specificity and
window length (S1 Table). In contrast to other TRIs, where there is just one test or algorithm,
Inno-Lia thus provides a whole panel of tools for assessing each specimen. This has distinctly
more power to identify true changes in the proportion of incident infections than any other
single serologic TRI. As can be seen in Fig 1 (top panels), there is considerable variation in the
incident infection estimates based on individual algorithms. We have pointed out previously
that it would be impossible to select a “best curve”, and the reliability derives from the combi-
nation of different algorithms [17]. The low and changing specificity of the BED incidence
assay [25,44] has prompted others to resort to additional criteria for assessment of incident
HIV infections. A multi-assay algorithm for HIV incidence that includes the BED incidence
EIA, an antibody avidity assay, HIV load, and CD4+ T-cell count has been shown to have excel-
lent specificity [45]. This approach has also been used successfully in order to determine HIV
incidence in cohort studies in which the needed additional information is easily available [46].
At the time of HIV diagnosis, such information is frequently not available, however, and the
advantage of our model consists of the fact that such information is not needed and that no
additional test has to be performed. Thus, similar to our approach, a bead based multiplex
assay that measures both the levels and the avidity of antibodies to various HIV-1 antigens and
detects recent HIV-1 infections with high sensitivity, specificity and robustness has been devel-
oped and evaluated recently [47,48].
Regarding the Inno-Lia, the use of an HIV confirmation assay for incident infection surveil-
lance is a further advantage, because data were available from virtually all newly diagnosed
patients. Once the system was well established, i.e., from the third year onward, 98% or more of
the notifications contained Inno-Lia data. Therefore, the incident infection estimates are truly
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representative. In comparison, the French monitoring system for incident HIV infection,
which combines a mandatory notification of all newly diagnosed cases with an enzyme immu-
noassay for recent infection performed on dried serum spot samples sent to a central labora-
tory, had an overall coverage of 76.5% between 2003 and 2008 [11]. The British monitoring
system, which combines a mandatory case notification with an avidity assay performed in a
central laboratory, had an avidity test coverage which increased from 24% in 2009 to 52% in
2011 and averaged 38.4% [12].
Inno-Lia based incident infection surveillance does not require additional tests, nor is ship-
ping of samples to a central lab required. Whether one uses a single algorithm or a combination
of different ones has no effect on costs, as these population-based evaluations, once set up, can
be performed in an automated way, e.g. by pasting the Inno-Lia dataset into a simple, pre-
formed Microsoft Excel-based evaluation table.
We demonstrated earlier that the result of the Inno-Lia algorithms in ART-naïve patients is
not affected by the severity of the immunodeficiency [16]. Therefore, Inno-Lia based surveil-
lance of incident infection does not require prior exclusion of the patients who are in an
advanced stage of disease. We showed in the same study that the clade of HIV-1 does not influ-
ence the incidence result. Technically, the method should thus also be feasible for countries
that have an HIV-1 clade distribution different from that of Switzerland, where subtype B
dominates the newly diagnosed infections with about 60% (analysis based on the sequences of
2670 new patients entered into the national HIV resistance database from 2009–2012). Of
course, such a transfer would need extensive validation prior to implementation.
The Inno-Lia is a relatively costly test that will be unaffordable for many low-income set-
tings. However, for countries already using this test, its further utilization for nationwide
assessment of incident infection can provide an additional public health benefit that is obtained
at virtually no additional costs. In the Swiss testing system, Inno-Lia is restricted to patients
with a reactive result in two, preferentially different, 4th generation screening tests, i.e. two
independent tests of equally high diagnostic specificity [49,50]. Thus, only few Inno-Lia tests
are performed unnecessarily due to false-positive screening result. At a specificity of 99% for
each of the two screening tests (the CE-marking rules actually request a specificity of 99.5% or
higher [51]), the combined specificity is 99.99%. Out of 100’000 tested uninfected individuals
only 10 would have undergone Inno-Lia testing in addition to those truly infected. Based on
the 3’851 HIV-positive individuals of this study, and assuming that maximally 3 million HIV
screenings were conducted in Switzerland during the six years, it is expected that 3’851
+ 300 = 4’151 Inno-Lia tests would have been conducted in total. At the current compensation
of CHF 132 per test, the total costs for the Inno-Lia testing amounted to approximately CHF
548’000, or CHF 92’000 per year. This is less than 1% of the costs of HIV screening which, at
CHF 20 per test, would amount to 10 Million CHF per year. Based on HIV-prevalence and kit
prices in other countries (the latter most likely being lower than in Switzerland), costs are likely
to differ for other settings.
In conclusion, our Inno-Lia based surveillance system shows a continuous overall reduction
of incident HIV-1 infections by 50% in Switzerland from 2008 to 2013, even for 2012 when
notifications increased by 15%. The decline was true for all major transmission modes, MSM,
HET and IDU. As the Inno-Lia algorithms perform equally well for the various HIV-1 sub-
types, the method should be technically feasible also for countries that have an HIV-1 subtype
distribution different from that of Switzerland. The Inno-Lia based assessment of incident HIV
infection ratios can be performed without a need for clinical information other than that the
patients are treatment-naïve, a requirement always met when newly diagnosing HIV infection
in an individual patient. Cost-wise, the system is particularly attractive for countries which
already use the Inno-Lia for confirmation of HIV infection and differentiation between HIV-1
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and HIV-2. For these, the Inno-Lia based incident infection assessment represents a free, addi-
tional public health benefit of the use of this relatively costly test.
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